Lacosamide Tablet, Film Coated
Product Images NDC 33342-304

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 33342-304). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

125 (Lacosamide 100mg 60s)

Label for Lacosamide Tablets USP 100 mg oral film-coated tablets. The label shows 60 tablets per container, distributed by Macleods Pharma USA and manufactured by Macleods Pharmaceuticals Ltd in India. Instructions include storage at 20 to 25°C and dispensing with a medication guide. The label has barcodes and dosage information.*

FDA Label Image

313 (Lacosamide 150mg 60s)

Label for Lacosamide Tablets, USP 150 mg, film-coated oral tablets by Macleods Pharmaceuticals Limited. The label states storage conditions, dispensing instructions, and the manufacturer as Macleods Pharma USA, Inc. It also indicates the package contains 60 tablets and includes barcodes and code number information.*

FDA Label Image

000 (Lacosamide 200mg 60s)

Lacosamide Tablets USP 200 mg film-coated oral tablets label by Macleods Pharmaceuticals Limited. The label includes dosage strength 200 mg, NDC 33342-305-09, contains 60 tablets, and storage instructions. It specifies manufacturing by Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd., India.*

FDA Label Image

369 (Lacosamide 50mg 60s)

Lacosamide 50 mg film-coated tablets label from Macleods Pharmaceuticals Limited. The label indicates 60 tablets per package for oral use. It includes storage instructions and dispensing information, with manufacturer details from Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. India.*

FDA Label Image

112 (Lacosamide Fig1)

A bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' comparing placebo and Lacosamide at various dosages across three studies. The vertical axis shows seizure reduction percentage, with Lacosamide bars generally higher than placebo, indicating percent decrease in seizure frequency by dose and study group.*

FDA Label Image

113 (Lacosamide Fig2)

A line chart titled "Proportion of Patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4." The y-axis represents Responder Rate as equal to or greater than improvement from -100% to 100%. The x-axis shows Percent of Patients from 0 to 100%. Four lines represent different groups: Placebo, Lacosamide 200 mg/day, Lacosamide 400 mg/day, and Lacosamide 600 mg/day, each with distinct line styles.*

FDA Label Image

Fig-3 (Lacosamide Fig3)

A Kaplan-Meier curve comparing the proportion of patients over time (days) between two groups: Lacosamide and Placebo. The graph shows patient survival or event-free proportion, with Lacosamide group consistently higher than Placebo. Additional statistics include a p-value of 0.001, hazard ratio (HR) of 0.548 representing a 45.2% risk reduction, and a 95% confidence interval from 0.381 to 0.788. Below the x-axis is the number of patients at risk at multiple time points for each group.*

FDA Label Image

111 (Lacosamide Str)

Chemical structure diagram of the active ingredient Lacosamide, showing its molecular arrangement including amide and benzyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.